Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …

Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been
substantially improved with the emergence of novel therapeutic agents, such as proteasome …

Bispecific T cell engagers (TCEs) have shown promise in the treatment of various cancers,
but the immunological mechanism and molecular determinants of primary and acquired …

Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and
extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM …

Chimeric antigen receptor T cells (CAR-T cells) have emerged as a potentially
transformative new approach to treating hematological malignancies. Ide-cel, an autologous …

Despite significant advances in the treatment of multiple myeloma which had led to
unprecedented rates of response and survival, patients still relapse, and cure remains …

Abstract Deciphering Multiple Myeloma evolution in the whole bone marrow is key to inform
curative strategies. Here, we perform spatial-longitudinal whole-exome sequencing …

Human bone marrow permanently harbors high numbers of neutrophils, and a tumor-
supportive bias of these cells could significantly impact bone marrow-confined …

Almost all biomedical research to date has relied upon mean measurements from cell
populations, however it is well established that what it is observed at this macroscopic level …

A lack of models that recapitulate the complexity of human bone marrow has hampered
mechanistic studies of normal and malignant hematopoiesis and the validation of novel …